-

01:58:39 PM

AXNX Stock News

AXNX - Axonics Inc

05/05/22 4:01 PM

Nasdaq : AXNX

earnings

Axonics® Reports First Quarter 2022 Financial Results

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. “We are pleased with this quarter’ s revenue result considering the significant impact the Omicron surge had on elective...

RHEA-AI

neutral

04/26/22 6:00 AM

Nasdaq : AXNX

conferences

Axonics® to Participate in BofA Securities 2022 Healthcare Conference

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022. Axonics is scheduled to present at 12:20 p.m. Eastern Time. About Axonics Based in Irvine, Calif., Axonics is a global...

RHEA-AI

neutral

04/19/22 6:00 AM

Nasdaq : AXNX

Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate...

RHEA-AI

neutral

04/14/22 4:01 PM

Nasdaq : AXNX

conferencesearnings

Axonics® to Report First Quarter 2022 Financial Results on May 5

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.

RHEA-AI

neutral

04/04/22 6:00 AM

Nasdaq : AXNX

Axonics® Launches Direct to Consumer Television Advertising Campaign

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign. The advertisements feature women with urinary incontinence that have been treated with Axonics sacral...

RHEA-AI

neutral

03/07/22 4:01 PM

Nasdaq : AXNX

fda approval

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved its newly developed, long-lived, recharge-free sacral neuromodulation implantable neurostimulator. “Axonics is keenly...

RHEA-AI

neutral

02/24/22 4:01 PM

Nasdaq : AXNX

earnings

Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2021. “We are proud of our fourth quarter and fiscal year 2021 results considering the disruption Covid-19 has...

RHEA-AI

neutral

02/03/22 6:00 AM

Nasdaq : AXNX

conferencesearnings

Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022. In conjunction with the release, Axonics will host a conference call at...

RHEA-AI

neutral

02/01/22 6:00 AM

Nasdaq : AXNX

conferences

Axonics® to Participate in SVB Leerink Virtual Healthcare Conference

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022. Axonics is scheduled to present at 12:00 p.m. Eastern Time. Based in Irvine, Calif., Axonics is a global...

RHEA-AI

neutral

01/25/22 6:00 AM

Nasdaq : AXNX

New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence prevalence in the U.S.. The overall prevalence of UI in adult U.S. women 20 years and older is...

RHEA-AI

neutral

1 2 3 4 5 6 Next

AXNX Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.axonicsmodulation.com
CeoRaymond Cohen
Security nameAxonics Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees416
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address26 Technology Dr
StateCalifornia
CityIrvine
Zip92618-2380
CountryUS
Phone19493966322

About Axonics Inc

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers a best-in-class urethral bulking agent for women with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. Stress urinary incontinence affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.